Review article: Risk of cardiovascular events in patients with inflammatory bowel disease receiving small molecule drugs
暂无分享,去创建一个
[1] S. Vermeire,et al. Etrasimod as induction and maintenance therapy for ulcerative colitis (ELEVATE): two randomised, double-blind, placebo-controlled, phase 3 studies , 2023, The Lancet.
[2] L. Peyrin-Biroulet,et al. P476 Characterization of cardiac conduction abnormalities reported in the phase 3 ELEVATE programme , 2023, Journal of Crohn's & Colitis.
[3] H. Huhtala,et al. Increasing incidence of inflammatory bowel disease with greatest change among the elderly: a nationwide study in Finland, 2000-2020. , 2022, Journal of Crohn's & colitis.
[4] C. Ponsioen,et al. Effectiveness and safety of tofacitinib for ulcerative colitis: two‐year results of the ICC Registry , 2022, Alimentary pharmacology & therapeutics.
[5] E. Loftus,et al. Multicenter Real-world Experience of Upadacitinib in the Treatment of Crohn's Disease. , 2022, Journal of Crohn's & Colitis.
[6] J. Silverberg,et al. Safety of upadacitinib in moderate-to-severe atopic dermatitis: An integrated analysis of phase 3 studies. , 2022, The Journal of allergy and clinical immunology.
[7] Deepak L. Bhatt,et al. Risk of major adverse cardiovascular events with tofacitinib versus tumour necrosis factor inhibitors in patients with rheumatoid arthritis with or without a history of atherosclerotic cardiovascular disease: a post hoc analysis from ORAL Surveillance , 2022, Annals of the Rheumatic Diseases.
[8] B. Sands,et al. Tofacitinib for the Treatment of Ulcerative Colitis: An Integrated Summary of up to 7.8 Years of Safety Data from the Global Clinical Programme , 2022, Journal of Crohn's & colitis.
[9] Biao Zhu,et al. Case Report: Treatment for steroid-refractory immune-related myocarditis with tofacitinib , 2022, Frontiers in Immunology.
[10] L. Peyrin-Biroulet,et al. Is selectivity the JAKpot winner for IBD treatment? , 2022, Gastroenterology.
[11] M. Dubinsky,et al. Review article: guide to tofacitinib dosing in patients with ulcerative colitis , 2022, Alimentary pharmacology & therapeutics.
[12] M. Buttmann,et al. OzEAN Study to Collect Real-World Evidence of Persistent Use, Effectiveness, and Safety of Ozanimod Over 5 Years in Patients With Relapsing-Remitting Multiple Sclerosis in Germany , 2022, Frontiers in Neurology.
[13] L. Peyrin-Biroulet,et al. Evaluating Upadacitinib in the Treatment of Moderate-to-Severe Active Ulcerative Colitis: Design, Development, and Potential Position in Therapy , 2022, Drug design, development and therapy.
[14] K. Allin,et al. The Risk of Type 2 Diabetes in Patients With Inflammatory Bowel Disease After Bowel Resections: A Nationwide Cohort Study , 2022, Gastro hep advances.
[15] C. Nelson,et al. Filgotinib: A Clinical Pharmacology Review , 2022, Clinical Pharmacokinetics.
[16] C. J. van der Woude,et al. Lipid Changes After Induction Therapy in Patients with Inflammatory Bowel Disease: Effect of Different Drug Classes and Inflammation , 2022, Inflammatory bowel diseases.
[17] S. Vermeire,et al. Upadacitinib as induction and maintenance therapy for moderately to severely active ulcerative colitis: results from three phase 3, multicentre, double-blind, randomised trials , 2022, The Lancet.
[18] L. Peyrin-Biroulet,et al. Is it time to include older adults in inflammatory bowel disease trials? A call for action. , 2022, The Lancet. Healthy longevity.
[19] S. Jung,et al. The Comparative Risk of Serious Adverse Events With Tofacitinib and TNF Inhibitors in Patients With Ulcerative Colitis: The Korean Experience as Revealed by a National Database , 2022, Journal of Korean medical science.
[20] D. Rubin,et al. Ozanimod in the Treatment of Ulcerative Colitis: Initial Real World Data from A Large Tertiary Center. , 2022, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.
[21] A. Cheifetz,et al. Review article: emerging drug therapies in inflammatory bowel disease , 2022, Alimentary pharmacology & therapeutics.
[22] Ousmane A Camara,et al. Long-Term Effectiveness, Safety and Tolerability of Fingolimod in Patients with Multiple Sclerosis in Real-World Treatment Settings in France: The VIRGILE Study , 2022, Neurology and Therapy.
[23] T. Cai,et al. Comparative Risk of Thrombotic and Cardiovascular Events with Tofacitinib and Anti-TNF Agents in Patients with Inflammatory Bowel Diseases , 2022, Digestive Diseases and Sciences.
[24] Deepak L. Bhatt,et al. Cardiovascular and Cancer Risk with Tofacitinib in Rheumatoid Arthritis. , 2022, The New England journal of medicine.
[25] B. Feagan,et al. Janus Kinase Inhibitors for the Management of Patients With Inflammatory Bowel Disease. , 2022, Gastroenterology & hepatology.
[26] P. Goupille,et al. Safety Profile of Upadacitinib up to 3 Years in Psoriatic Arthritis: An Integrated Analysis of Two Pivotal Phase 3 Trials , 2021, Rheumatology and Therapy.
[27] M. Zhong,et al. Risk for Cardiovascular Adverse Events Associated With Sphingosine-1-Phosphate Receptor Modulators in Patients With Multiple Sclerosis: Insights From a Pooled Analysis of 15 Randomised Controlled Trials , 2021, Frontiers in Immunology.
[28] J. Ge,et al. Case Series of Steroid-Resistant Immune Checkpoint Inhibitor Associated Myocarditis: A Comparative Analysis of Corticosteroid and Tofacitinib Treatment , 2021, Frontiers in Pharmacology.
[29] G. D'Haens,et al. Upadacitinib Was Efficacious and Well Tolerated Over 30 Months in Patients with Crohn's Disease in the CELEST Extension Study. , 2021, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.
[30] Long Millie,et al. P038 Ozanimod First-Dose Cardiac Effects in Patients with Moderately to Severely Active Ulcerative Colitis and Relapsing Multiple Sclerosis. , 2021, American Journal of Gastroenterology.
[31] T. Hibi,et al. A Phase II, Multicentre, Randomised, Double-Blind, Placebo-Controlled Study to Evaluate Safety, Tolerability and Efficacy of Amiselimod in Patients with Moderate to Severe Active Crohn's Disease. , 2021, Journal of Crohn's & colitis.
[32] M. Genovese,et al. Integrated safety analysis of filgotinib in patients with moderately to severely active rheumatoid arthritis receiving treatment over a median of 1.6 years , 2021, Annals of the Rheumatic Diseases.
[33] S. Hanauer,et al. Ozanimod as Induction and Maintenance Therapy for Ulcerative Colitis. , 2021, The New England journal of medicine.
[34] W. Miles,et al. Physiologic Variants of Cardiac Conduction (Aberration, Gap, Supernormal Conduction). , 2021, Cardiac electrophysiology clinics.
[35] S. Ng,et al. International consensus on the prevention of venous and arterial thrombotic events in patients with inflammatory bowel disease , 2021, Nature Reviews Gastroenterology & Hepatology.
[36] S. Vermeire,et al. Filgotinib as induction and maintenance therapy for ulcerative colitis (SELECTION): a phase 2b/3 double-blind, randomised, placebo-controlled trial , 2021, The Lancet.
[37] S. Bonovas,et al. Safety of S1P Modulators in Patients with Immune-Mediated Diseases: A Systematic Review and Meta-Analysis , 2021, Drug Safety.
[38] C. Taxonera,et al. Real-World Effectiveness and Safety of Tofacitinib in Patients With Ulcerative Colitis: Systematic Review With Meta-Analysis. , 2021, Inflammatory bowel diseases.
[39] S. Vermeire,et al. Long-term Safety and Efficacy of Etrasimod for Ulcerative Colitis: Results from the Open-label Extension of the OASIS Study , 2021, Journal of Crohn's & colitis.
[40] S. Vermeire,et al. Long-Term Efficacy and Safety of Ozanimod in Moderately to Severely Active Ulcerative Colitis: Results From the Open-Label Extension of the Randomized, Phase 2 TOUCHSTONE Study , 2021, Journal of Crohn's & colitis.
[41] M. Regueiro,et al. Tofacitinib Treatment Safety in Moderate to Severe Ulcerative Colitis: Comparison of Observational Population Cohort Data From the IBM MarketScan® Administrative Claims Database With Tofacitinib Trial Data , 2020, Inflammatory bowel diseases.
[42] D. Rubin,et al. Real-World Effectiveness and Safety of Tofacitinib in Crohn's Disease and IBD-U: A Multi-Center Study from the TROPIC consortium. , 2020, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.
[43] G. Kaplan,et al. The four epidemiological stages in the global evolution of inflammatory bowel disease , 2020, Nature Reviews Gastroenterology & Hepatology.
[44] S. Rizzo,et al. Inflammation as a Predictor of Recurrent Ventricular Tachycardia After Ablation in Patients With Myocarditis. , 2020, Journal of the American College of Cardiology.
[45] J. Cerqueira,et al. REALMS study: real-world effectiveness and safety of fingolimod in patients with relapsing-remitting multiple sclerosis in Portugal , 2020, Neurological Sciences.
[46] J. Gisbert,et al. Tofacitinib in Ulcerative Colitis: Real-world Evidence From the ENEIDA Registry. , 2020, Journal of Crohn's & colitis.
[47] Hongwei Lu,et al. The role of sphingosine 1‐phosphate and its receptors in cardiovascular diseases , 2020, Journal of cellular and molecular medicine.
[48] S. Vermeire,et al. JAK Inhibitors: Back to Small Molecules for the Treatment of IBD , 2020, Journal of Crohn's & colitis.
[49] D. Rubin,et al. Safety of Tofacitinib in a Real-World Cohort of Patients With Ulcerative Colitis. , 2020, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.
[50] T. Card,et al. Disease Activity in Inflammatory Bowel Disease Is Associated With Arterial Vascular Disease. , 2020, Inflammatory bowel diseases.
[51] G. D'Haens,et al. Ozanimod induction therapy for patients with moderate to severe Crohn's disease: a single-arm, phase 2, prospective observer-blinded endpoint study. , 2020, The lancet. Gastroenterology & hepatology.
[52] K. Ohtsuka,et al. Rapid prediction of 1-year efficacy of tofacitinib for treating refractory ulcerative colitis , 2020, Intestinal research.
[53] S. Danese,et al. JAK selectivity: more precision less troubles , 2020, Expert review of gastroenterology & hepatology.
[54] C. Campochiaro,et al. Therapeutic strategies for virus-negative myocarditis: a comprehensive review. , 2020, European journal of internal medicine.
[55] Xiaoxu Zhou,et al. Evidence for Inflammation as a Driver of Atrial Fibrillation , 2020, Frontiers in Cardiovascular Medicine.
[56] R. Weersma,et al. Tofacitinib for ulcerative colitis: results of the prospective Dutch Initiative on Crohn and Colitis (ICC) registry , 2020, Alimentary pharmacology & therapeutics.
[57] S. Vermeire,et al. JAK–STAT pathway targeting for the treatment of inflammatory bowel disease , 2020, Nature Reviews Gastroenterology & Hepatology.
[58] S. Rizzo,et al. Ventricular Arrhythmias in Myocarditis: Characterization and Relationships With Myocardial Inflammation. , 2020, Journal of the American College of Cardiology.
[59] M. Grabowski,et al. Cardiac Arrhythmias in Autoimmune Diseases. , 2020, Circulation journal : official journal of the Japanese Circulation Society.
[60] P. Higgins,et al. Efficacy of Upadacitinib in a Randomized Trial of Patients With Active Ulcerative Colitis. , 2020, Gastroenterology.
[61] J. Lewis,et al. Efficacy and Safety of Upadacitinib in a Randomized Trial of Patients With Crohn's Disease. , 2020, Gastroenterology.
[62] Stanley B. Cohen,et al. Safety profile of upadacitinib in rheumatoid arthritis: integrated analysis from the SELECT phase III clinical programme , 2019, Annals of the Rheumatic Diseases.
[63] K. Allin,et al. Inflammatory Bowel Disease Increases Risk of Type 2 Diabetes in a Nationwide Cohort Study. , 2020, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.
[64] B. Sands,et al. Tofacitinib Treatment Is Associated With Modest and Reversible Increases in Serum Lipids in Patients With Ulcerative Colitis. , 2020, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.
[65] Zhuoli Zhang,et al. Effect of tofacitinib on cardiovascular events and all-cause mortality in patients with immune-mediated inflammatory diseases: a systematic review and meta-analysis of randomized controlled trials , 2019, Therapeutic advances in musculoskeletal disease.
[66] A. Amiot,et al. Real-world evidence of tofacitinib effectiveness and safety in patients with refractory ulcerative colitis. , 2019, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.
[67] S. Vermeire,et al. Efficacy and Safety of Etrasimod in a Phase 2 Randomized Trial of Patients with Ulcerative Colitis. , 2019, Gastroenterology.
[68] D. Gladman,et al. Changes in Lipid Levels and Incidence of Cardiovascular Events Following Tofacitinib Treatment in Patients With Psoriatic Arthritis: A Pooled Analysis Across Phase III and Long‐Term Extension Studies , 2019, Arthritis care & research.
[69] E. Cristiano,et al. Real-World Effectiveness and Safety of Fingolimod in Patients With Relapsing Remitting Multiple Sclerosis: A Prospective Analysis in Buenos Aires, Argentina. , 2019, Clinical neuropharmacology.
[70] I. McInnes,et al. Risk Factors for Major Adverse Cardiovascular Events in Phase III and Long‐Term Extension Studies of Tofacitinib in Patients With Rheumatoid Arthritis , 2019, Arthritis & rheumatology.
[71] L. Peyrin-Biroulet,et al. Comorbidities in inflammatory bowel disease: a call for action. , 2019, The lancet. Gastroenterology & hepatology.
[72] G. Kaplan,et al. Evolving Epidemiology of IBD , 2019, Current Gastroenterology Reports.
[73] C. Le Berre,et al. JAK selectivity for inflammatory bowel disease treatment: does it clinically matter? , 2019, Gut.
[74] S. Rizzo,et al. Arrhythmias in myocarditis: State of the art. , 2019, Heart rhythm.
[75] S. Rizzo,et al. Impact of systemic immune-mediated diseases on clinical features and prognosis of patients with biopsy-proved myocarditis. , 2019, International journal of cardiology.
[76] W. Sandborn,et al. Targeting Cytokine Signaling and Lymphocyte Traffic via Small Molecules in Inflammatory Bowel Disease: JAK Inhibitors and S1PR Agonists , 2019, Front. Pharmacol..
[77] J. S. Kim,et al. Increased Risk of Diabetes in Inflammatory Bowel Disease Patients: A Nationwide Population-Based Study in Korea , 2019, Journal of clinical medicine.
[78] D. Rubin,et al. Real-World Experience with Tofacitinib in IBD at a Tertiary Center , 2019, Digestive Diseases and Sciences.
[79] M. Floria,et al. Cardiovascular Manifestations of Inflammatory Bowel Disease: Pathogenesis, Diagnosis, and Preventive Strategies , 2019, Gastroenterology research and practice.
[80] B. Nordestgaard,et al. Cardiovascular Risk Profile Among Patients With Inflammatory Bowel Disease: A Population-based Study of More Than 100 000 Individuals , 2018, Journal of Crohn's & colitis.
[81] N. Harrison,et al. Heart Under Attack: Cardiac Manifestations of Inflammatory Bowel Disease. , 2018, Inflammatory bowel diseases.
[82] H. Sokol,et al. Clinical activity is an independent risk factor of ischemic heart and cerebrovascular arterial disease in patients with inflammatory bowel disease , 2018, PloS one.
[83] Ludwig Kappos,et al. Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study , 2018, The Lancet.
[84] V. van Pesch,et al. Long-term safety and real-world effectiveness of fingolimod in relapsing multiple sclerosis , 2017, Patient related outcome measures.
[85] U. Eriksson,et al. Diagnosis and management of myocardial involvement in systemic immune-mediated diseases: a position statement of the European Society of Cardiology Working Group on Myocardial and Pericardial Disease , 2017, European heart journal.
[86] E. Armstrong,et al. Effect of tofacitinib on lipid levels and lipid-related parameters in patients with moderate to severe psoriasis. , 2017, Journal of clinical lipidology.
[87] P. Libby,et al. Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease , 2017, The New England journal of medicine.
[88] F. Carrat,et al. Increased risk of acute arterial events in young patients and severely active IBD: a nationwide French cohort study , 2017, Gut.
[89] J. Gisbert,et al. Cardiovascular disease in immune-mediated inflammatory diseases , 2017, Medicine.
[90] J. L. Ruiz-Peña,et al. The real-world effectiveness and safety of fingolimod in relapsing-remitting multiple sclerosis patients: An observational study , 2017, PloS one.
[91] G. Keskindemirci,et al. Prolonged P-Wave and QT Dispersion in Children with Inflammatory Bowel Disease in Remission , 2017, BioMed research international.
[92] L. Peyrin-Biroulet,et al. JAK inhibition in inflammatory bowel disease , 2017, Expert review of clinical immunology.
[93] S. Vermeire,et al. Tofacitinib for induction and maintenance therapy of Crohn's disease: results of two phase IIb randomised placebo-controlled trials , 2017, Gut.
[94] Андрей Юрьевич Барановский. Clinical remission in patients with moderate-to-severe Crohn's disease treated with filgotinib (the FITZROY study): results from a phase 2, double-blind, randomised, placebo-controlled trial (статья) , 2017 .
[95] W. Sandborn,et al. Tofacitinib as Induction and Maintenance Therapy for Ulcerative Colitis. , 2017, The New England journal of medicine.
[96] L. Peyrin-Biroulet,et al. Next generation of small molecules in inflammatory bowel disease , 2016, Gut.
[97] M. González-Gay,et al. Effects of tofacitinib and other DMARDs on lipid profiles in rheumatoid arthritis: implications for the rheumatologist. , 2016, Seminars in arthritis and rheumatism.
[98] G. Aksan,et al. Assessment of Atrial Electromechanical Delay and Left Atrial Mechanical Functions in Patients with Ulcerative Colitis , 2016, Echocardiography.
[99] M. Zeegers,et al. Epidemiology and Long-term Outcome of Inflammatory Bowel Disease Diagnosed at Elderly Age—An Increasing Distinct Entity? , 2016, Inflammatory bowel diseases.
[100] Y. Coşkun,et al. Atrial Electromechanical Properties in Inflammatory Bowel Disease , 2016, Echocardiography.
[101] S. Vermeire,et al. Ozanimod Induction and Maintenance Treatment for Ulcerative Colitis. , 2016, The New England journal of medicine.
[102] R. Gajulapalli,et al. Prevalence of QT interval prolongation in inflammatory bowel disease. , 2016, The Turkish journal of gastroenterology : the official journal of Turkish Society of Gastroenterology.
[103] S. Kapadia,et al. Conventional risk factors and cardiovascular outcomes of patients with inflammatory bowel disease with confirmed coronary artery disease. , 2014, Inflammatory bowel diseases.
[104] Ken Kitahara,et al. Analysis of Onset Mechanisms of a Sphingosine 1-Phosphate Receptor Modulator Fingolimod-Induced Atrioventricular Conduction Block and QT-Interval Prolongation. , 2014, Toxicology and applied pharmacology.
[105] Jeffrey A. Cohen,et al. First-dose effects of fingolimod: Pooled safety data from three phase 3 studies. , 2014, Multiple sclerosis and related disorders.
[106] W. Sandborn,et al. A phase 2 study of tofacitinib, an oral Janus kinase inhibitor, in patients with Crohn's disease. , 2014, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.
[107] Jennifer G. Robinson,et al. 2013 ACC/AHA Guideline on the Assessment of Cardiovascular Risk: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines , 2014, Circulation.
[108] Jennifer G. Robinson,et al. 2013 ACC/AHA Guideline on the Assessment of Cardiovascular Risk: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines , 2014, Circulation.
[109] L. Dauchet,et al. Thromboembolic events and cardiovascular mortality in inflammatory bowel diseases: a meta-analysis of observational studies. , 2014, Journal of Crohn's & colitis.
[110] R. Erichsen,et al. Increased risk of atrial fibrillation and stroke during active stages of inflammatory bowel disease: a nationwide study. , 2014, Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology.
[111] Siddharth Singh,et al. Risk of cerebrovascular accidents and ischemic heart disease in patients with inflammatory bowel disease: a systematic review and meta-analysis. , 2014, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.
[112] Mark E Flanagan,et al. Discovery and development of Janus kinase (JAK) inhibitors for inflammatory diseases. , 2014, Journal of medicinal chemistry.
[113] Yeong-Wook Song,et al. Open-label tofacitinib and double-blind atorvastatin in rheumatoid arthritis patients: a randomised study* , 2013, Annals of the rheumatic diseases.
[114] R. Erichsen,et al. Disease Activity in Inflammatory Bowel Disease Is Associated with Increased Risk of Myocardial Infarction, Stroke and Cardiovascular Death – A Danish Nationwide Cohort Study , 2013, PloS one.
[115] L. Dauchet,et al. Natural history of elderly-onset inflammatory bowel disease: a population-based cohort study , 2013, Gut.
[116] H. Yorulmaz,et al. Prolonged QT dispersion in inflammatory bowel disease. , 2013, World journal of gastroenterology.
[117] N. Gray,et al. The selective sphingosine 1-phosphate receptor modulator BAF312 redirects lymphocyte distribution and has species-specific effects on heart rate , 2012, British journal of pharmacology.
[118] A. Kornbluth,et al. Patients enrolled in randomized controlled trials do not represent the inflammatory bowel disease patient population. , 2012, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.
[119] W. Sandborn,et al. Tofacitinib, an oral Janus kinase inhibitor, in active ulcerative colitis. , 2012, The New England journal of medicine.
[120] K. Sonmez,et al. Evaluation of QT and P Wave Dispersion and Mean Platelet Volume among Inflammatory Bowel Disease Patients , 2011, International journal of medical sciences.
[121] G. Fishman,et al. The Cardiac Conduction System , 2011, Circulation.
[122] M. Curione,et al. A study on QT interval in patients affected with inflammatory bowel disease without cardiac involvement , 2010, Internal and emergency medicine.
[123] M. Curione,et al. Atrioventricular block associated with Crohn's relapsing colitis in a 12-year-old child. , 2010, Inflammatory bowel diseases.
[124] David Gruben,et al. The safety and efficacy of a JAK inhibitor in patients with active rheumatoid arthritis: Results of a double-blind, placebo-controlled phase IIa trial of three dosage levels of CP-690,550 versus placebo. , 2009, Arthritis and rheumatism.
[125] J. Brown,et al. Sphingosine-1-phosphate receptor signalling in the heart. , 2008, Cardiovascular research.
[126] B. Gersh,et al. The Problem With Composite End Points in Cardiovascular Studies: The Story of Major Adverse Cardiac Events and Percutaneous Coronary Intervention , 2009 .
[127] Kevin E. Kip,et al. The problem with composite end points in cardiovascular studies: the story of major adverse cardiac events and percutaneous coronary intervention. , 2008, Journal of the American College of Cardiology.
[128] Paul M. Ridker,et al. Inflammation as a Cardiovascular Risk Factor , 2004, Circulation.
[129] Sarah Spiegel,et al. Sphingosine-1-phosphate: an enigmatic signalling lipid , 2003, Nature Reviews Molecular Cell Biology.
[130] I. Leodolter. [Crohn's disease]. , 1967, Wiener Zeitschrift fur innere Medizin und ihre Grenzgebiete.
[131] G PLACITELLI,et al. [Ulcerative colitis]. , 1958, La Riforma medica.